片頭痛の世界市場 (～2032年)：タイプ・治療タイプ・薬剤クラス・地域別

世界の片頭痛の市場規模は、2023年の56億8,000万米ドル、2024年の60億米ドルから、予測期間中は3.83％のCAGRで推移し、2032年には84億2,000万米ドルの規模に成長すると予測されています。

新しい薬剤クラスに対する社会的認知の高まりと世界の片頭痛問題の増加が同市場の成長に影響を与える2つの主な要因です。また、カルシトニン遺伝子関連ペプチド (CGRP) の導入も成長を促進すると予想されています。片頭痛は再発性の激しい頭痛で、羞明、羞声、吐き気を伴います。疾患の進行には遺伝子が関与しています。落胆、緊張、不安、ショック、興奮など、バランスの崩れた感情が片頭痛を引き起こすことがあります。片頭痛発作の長さや強さはそれぞれ異なり、多くの場合、頭の片側に症状が出ます。片頭痛の頻度の増加、かなりの規模のアンメットニーズ、研究開発費の増加による医薬品パイプラインの充実、片頭痛と利用可能な治療法に関する理解の深まりなども同市場の成長に影響しています。

地域別展望

調査期間を通じて、アジア太平洋市場は顕著なCAGRが見込まれています。医療費が増加し、中国やインドなどの新興国のインフラが改善する中で、アジア太平洋市場は拡大すると予測されています。規制機関のイニシアチブの拡大により、片頭痛治療の選択肢がリーズナブルな価格で容易に入手できることも、この地域市場を推進している重要な側面です。

欧州は第2位の市場シェアを示しています。同市場の成長を牽引している2つの理由は、世界の片頭痛問題の増加と、新しい薬剤クラスに関する一般的知識の増加です。さらに、カルシトニン遺伝子関連ペプチド (CGRP) の発売もこの成長を支えるものと期待されています。

北米市場は2024年から2032年にかけてもっとも高いCAGRで成長すると予想されています。米国、カナダ、その他の国々で行われている、新規治療の選択肢を見出すための実質的な研究開発活動から、現地市場は利益を得ると予想されています。

当レポートでは、世界の片頭痛の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 促進要因
  • 片頭痛の発生率/有病率の増加
  • 片頭痛治療薬の承認増加
• 抑制要因
  • 参入企業による自主的な製品回収
• 機会
  • 片頭痛の有効性と安全性に関する進行中の臨床試験
• ポーターのファイブフォース分析
• COVID-19が世界の片頭痛市場に与える影響

第5章 世界の片頭痛市場：片頭痛タイプ別

• 概要
• 前兆を伴う片頭痛
• 前兆のない片頭痛
• その他

第6章 世界の片頭痛市場：治療タイプ別

• 概要
• 薬剤
  • CGRP阻害剤
  • トリプタン
  • 麦角
  • アセチルコリン阻害剤/神経毒
  • 非ステロイド性抗炎症薬 (NSAID)
  • ベータ遮断薬
  • カルシウムチャネル遮断薬
  • DITAN
  • その他
• デバイスベースの治療
  • 電気神経調節デバイス
  • 経頭蓋磁気刺激デバイス
  • 迷走神経刺激デバイス
  • その他

第7章 世界の片頭痛市場：流通チャネル別

• 概要
• オンライン
• オフライン

第8章 世界の片頭痛市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • ニュージーランド
  • その他
• その他の地域
  • 中東
  • ラテンアメリカ
  • アフリカ

第9章 競合情勢

• 市場シェア分析
• 競合ダッシュボード
• 公開企業の株式サマリー
• 比較分析：主要企業金融
• 主な展開・成長戦略

第10章 企業プロファイル

• AMGEN INC
• ELI LILLY AND COMPANY
• ABBVIE INC.
• BAUSCH HEALTH COMPANIES INC.
• GSK PLC
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• PFIZER INC.
• THERANICA BIO-ELECTRONICS LTD
• CEFALY
• ASTRAZENECA
• DATA CITATIONS

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 3 GLOBAL MIGRAINE MARKET, FOR MIGRAINE WITH AURA, BY REGION, 2019-2032 (USD MILLION)
• TABLE 4 GLOBAL MIGRAINE MARKET, FOR MIGRAINE WITHOUT AURA, BY REGION, 2019-2032 (USD MILLION)
• TABLE 5 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 6 GLOBAL MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 7 GLOBAL MIGRAINE MARKET, FOR MEDICATION, BY REGION, 2019-2032 (USD MILLION)
• TABLE 8 GLOBAL MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 9 GLOBAL MIGRAINE MARKET, FOR CGRP INHIBITORS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 10 GLOBAL MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 11 GLOBAL MIGRAINE MARKET, FOR RIMEGEPANT, BY REGION, 2019-2032 (USD MILLION)
• TABLE 12 GLOBAL MIGRAINE MARKET, FOR UBROGEPANT, BY REGION, 2019-2032 (USD MILLION)
• TABLE 13 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 14 GLOBAL MIGRAINE MARKET, FOR TRIPTANS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 15 GLOBAL MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 16 GLOBAL MIGRAINE MARKET, FOR SUMATRIPTAN SUCCINATE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 17 GLOBAL MIGRAINE MARKET, FOR ZOLMITRIPTAN, BY REGION, 2019-2032 (USD MILLION)
• TABLE 18 GLOBAL MIGRAINE MARKET, FOR RIZATRIPTAN, BY REGION, 2019-2032 (USD MILLION)
• TABLE 19 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 20 GLOBAL MIGRAINE MARKET, FOR ERGOTS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 21 GLOBAL MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 22 GLOBAL MIGRAINE MARKET, FOR DIHYDROERGOTAMINE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 23 GLOBAL MIGRAINE MARKET, FOR ERGOTAMINE TARTRATE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 24 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 25 GLOBAL MIGRAINE MARKET, FOR ACETYLCHOLINE INHIBITORS/ NEUROTOXINS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 26 GLOBAL MIGRAINE MARKET, FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2019-2032 (USD MILLION)
• TABLE 27 GLOBAL MIGRAINE MARKET, FOR BETA-BLOCKERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 28 GLOBAL MIGRAINE MARKET, FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 29 GLOBAL MIGRAINE MARKET, FOR DITANS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 30 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 31 GLOBAL MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY REGION, 2019-2032 (USD MILLION)
• TABLE 32 GLOBAL MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 33 GLOBAL MIGRAINE MARKET, FOR ELECTRICAL NEUROMODULATION DEVICE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 34 GLOBAL MIGRAINE MARKET, FOR TRANSCRANIAL MAGNETIC STIMULATION DEVICE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 35 GLOBAL MIGRAINE MARKET, FOR VAGUS NERVE STIMULATION DEVICE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 36 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
• TABLE 37 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 38 GLOBAL MIGRAINE MARKET, FOR ONLINE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 39 GLOBAL MIGRAINE MARKET, FOR OFFLINE, BY REGION, 2019-2032 (USD MILLION)
• TABLE 40 GLOBAL MIGRAINE MARKET, BY REGION, 2019-2032 (USD MILLION)
• TABLE 41 NORTH AMERICA: MIGRAINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
• TABLE 42 NORTH AMERICA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 43 NORTH AMERICA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 44 NORTH AMERICA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 45 NORTH AMERICA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 46 NORTH AMERICA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 47 NORTH AMERICA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 48 NORTH AMERICA: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 49 NORTH AMERICA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 50 US: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 51 US: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 52 US: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 53 US: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 54 US: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 55 US: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 56 US: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 57 US: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 58 CANADA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 59 CANADA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 60 CANADA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 61 CANADA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 62 CANADA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 63 CANADA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 64 CANADA: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 65 CANADA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 66 EUROPE: MIGRAINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
• TABLE 67 EUROPE: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 68 EUROPE: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 69 EUROPE: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 70 EUROPE: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 71 EUROPE: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 72 EUROPE: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 73 EUROPE: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 74 EUROPE: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 75 GERMANY: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 76 GERMANY: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 77 GERMANY: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 78 GERMANY: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 79 GERMANY: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 80 GERMANY: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 81 GERMANY: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 82 GERMANY: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 83 FRANCE: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 84 FRANCE: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 85 FRANCE: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 86 FRANCE: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 87 FRANCE: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 88 FRANCE: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 89 FRANCE: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 90 FRANCE: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 91 UK: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 92 UK: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 93 UK: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 94 UK: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 95 UK: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 96 UK: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 97 UK: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 98 UK: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 99 ITALY: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 100 ITALY: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 101 ITALY: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 102 ITALY: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 103 ITALY: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 104 ITALY: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 105 ITALY: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 106 ITALY: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 107 SPAIN: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 108 SPAIN: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 109 SPAIN: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 110 SPAIN: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 111 SPAIN: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 112 SPAIN: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 113 SPAIN: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 114 SPAIN: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 115 REST OF EUROPE: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 116 REST OF EUROPE: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 117 REST OF EUROPE: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 118 REST OF EUROPE: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 119 REST OF EUROPE: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 120 REST OF EUROPE: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 121 REST OF EUROPE: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 122 REST OF EUROPE: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 123 ASIA-PACIFIC: MIGRAINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
• TABLE 124 ASIA-PACIFIC: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 125 ASIA-PACIFIC: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 126 ASIA-PACIFIC: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 127 ASIA-PACIFIC: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 128 ASIA-PACIFIC: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 129 ASIA-PACIFIC: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 130 ASIA-PACIFIC: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 131 ASIA-PACIFIC: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 132 CHINA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 133 CHINA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 134 CHINA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 135 CHINA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 136 CHINA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 137 CHINA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 138 CHINA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 139 CHINA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 140 INDIA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 141 INDIA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 142 INDIA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 143 INDIA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 144 INDIA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 145 INDIA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 146 INDIA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 147 INDIA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 148 JAPAN: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 149 JAPAN: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 150 JAPAN: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 151 JAPAN: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 152 JAPAN: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 153 JAPAN: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 154 JAPAN: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 155 JAPAN: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 156 SOUTH KOREA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 157 SOUTH KOREA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 158 SOUTH KOREA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 159 SOUTH KOREA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 160 SOUTH KOREA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 161 SOUTH KOREA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 162 SOUTH KOREA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 163 SOUTH KOREA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 164 AUSTRALIA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 165 AUSTRALIA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 166 AUSTRALIA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 167 AUSTRALIA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 168 AUSTRALIA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 169 AUSTRALIA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 170 AUSTRALIA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 171 AUSTRALIA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 172 NEW ZEALAND: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 173 NEW ZEALAND: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 174 NEW ZEALAND: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 175 NEW ZEALAND: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 176 NEW ZEALAND: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 177 NEW ZEALAND: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 178 NEW ZEALAND: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 179 NEW ZEALAND: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 180 REST OF ASIA-PACIFIC: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 181 REST OF ASIA-PACIFIC: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 182 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 183 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 184 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 185 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 186 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 187 REST OF ASIA-PACIFIC: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 188 REST OF THE WORLD MIGRAINE MARKET, BY REGION, 2019-2032 (USD MILLION)
• TABLE 189 REST OF THE WORLD: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 190 REST OF THE WORLD: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 191 REST OF THE WORLD: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 192 REST OF THE WORLD: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 193 REST OF THE WORLD: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 194 REST OF THE WORLD: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 195 REST OF THE WORLD: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019-2032 (USD MILLION)
• TABLE 196 REST OF THE WORLD: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 197 MIDDLE EAST: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 198 MIDDLE EAST: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 199 MIDDLE EAST: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 200 MIDDLE EAST: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 201 MIDDLE EAST: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 202 MIDDLE EAST: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 203 MIDDLE EAST: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019-2032 (USD MILLION)
• TABLE 204 MIDDLE EAST: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 205 LATIN AMERICA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 206 LATIN AMERICA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 207 LATIN AMERICA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 208 LATIN AMERICA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 209 LATIN AMERICA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 210 LATIN AMERICA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 211 LATIN AMERICA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019-2032 (USD MILLION)
• TABLE 212 LATIN AMERICA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 213 AFRICA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019-2032 (USD MILLION)
• TABLE 214 AFRICA: MIGRAINE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)
• TABLE 215 AFRICA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 216 AFRICA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 217 AFRICA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 218 AFRICA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019-2032 (USD MILLION)
• TABLE 219 AFRICA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019-2032 (USD MILLION)
• TABLE 220 AFRICA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
• TABLE 221 PRODUCT LAUNCH
• TABLE 222 AGREEMENT
• TABLE 223 PRODUCT APPROVAL
• TABLE 224 COLLABORATION
• TABLE 225 PRODUCT EXPANSION
• TABLE 226 AMGEN INC.: PRODUCTS OFFERED
• TABLE 227 AMGEN INC.: KEY DEVELOPMENTS
• TABLE 228 ELI LILLY AND COMPANY: PRODUCTS OFFERED
• TABLE 229 ELI LILLY AND COMPANY: KEY DEVELOPMENTS
• TABLE 230 ABBVIE INC.: PRODUCTS OFFERED
• TABLE 231 ABBVIE INC.: KEY DEVELOPMENTS
• TABLE 232 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED
• TABLE 233 GSK PLC: PRODUCTS OFFERED
• TABLE 234 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
• TABLE 235 SYSMEX CORPORATION: KEY DEVELOPMENTS
• TABLE 236 PFIZER INC: PRODUCT OFFERED
• TABLE 237 PFIZER INC: KEY DEVELOPMENTS
• TABLE 238 THERANICA BIO-ELECTRONICS LTD: PRODUCT OFFERED
• TABLE 239 THERANICA BIO-ELECTRONICS LTD: KEY DEVELOPMENTS
• TABLE 240 3M: PRODUCT OFFERED
• TABLE 241 ASTRAZENECA: PRODUCT OFFERED

LIST OF FIGURES

• FIGURE 1 GLOBAL MIGRAINE MARKET: STRUCTURE
• FIGURE 2 GLOBAL MIGRAINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
• FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
• FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MIGRAINE MARKET
• FIGURE 6 GLOBAL MIGRAINE MARKET MIGRAINE TYPE SEGMENT, 2023 & 2032 (USD MILLION)
• FIGURE 7 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE, 2023 & 2032 (USD MILLION)
• FIGURE 8 GLOBAL MIGRAINE MARKET SHARE (%), BY MIGRAINE TYPE, 2023
• FIGURE 9 GLOBAL MIGRAINE MARKET, TREATMENT SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
• FIGURE 10 GLOBAL MIGRAINE MARKET, BY TREATMENT, 2023 & 2032 (USD MILLION)
• FIGURE 11 GLOBAL MIGRAINE MARKET SHARE (%), BY TREATMENT, 2023
• FIGURE 12 GLOBAL MIGRAINE MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
• FIGURE 13 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION)
• FIGURE 14 GLOBAL MIGRAINE MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023
• FIGURE 15 GLOBAL MIGRAINE MARKET, BY REGION, 2023 & 2032 (USD MILLION)
• FIGURE 16 GLOBAL MIGRAINE MARKET SHARE (%), BY REGION, 2023
• FIGURE 17 NORTH AMERICA MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032 (USD MILLION)
• FIGURE 18 NORTH AMERICA: MIGRAINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
• FIGURE 19 NORTH AMERICA: MIGRAINE MARKET SHARE (%), BY COUNTRY, 2023
• FIGURE 20 EUROPE MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032 (USD MILLION)
• FIGURE 21 EUROPE: MIGRAINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
• FIGURE 22 EUROPE: MIGRAINE MARKET SHARE (%), BY COUNTRY, 2023
• FIGURE 23 ASIA-PACIFIC MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032
• FIGURE 24 ASIA-PACIFIC: MIGRAINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
• FIGURE 25 ASIA-PACIFIC: MIGRAINE MARKET SHARE (%), BY COUNTRY, 2023
• FIGURE 26 REST OF THE WORLD MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032 (USD MILLION)
• FIGURE 27 REST OF THE WORLD: MIGRAINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
• FIGURE 28 REST OF THE WORLD: MIGRAINE MARKET SHARE, BY COUNTRY, 2023 (%)
• FIGURE 29 GLOBAL MIGRAINE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
• FIGURE 30 COMPETITOR DASHBOARD: GLOBAL MIGRAINE MARKET
• FIGURE 31 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 32 AMGEN INC.: SWOT ANALYSIS
• FIGURE 33 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 34 ELI LILLY AND COMPANY: SWOT ANALYSIS
• FIGURE 35 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 36 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 37 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 38 GSK PLC: SWOT ANALYSIS
• FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
• FIGURE 41 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 42 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 43 ASTRAZENECA: SWOT ANALYSIS

Global Migraine Market Research Report Information by Type (Episodic and Chronic), By Treatment Type (Preventive, Abortive), By Drug Class (Triptans, Ergots, and Others), And by Region (North America, Europe, Asia-Pacific, And Rest of The World) Market Forecast Till 2032

Overview of the Market

In 2023, the migraine market was estimated to be worth USD 5.68 billion. The global migraine market is expected to expand at a compound annual growth rate (CAGR) of 3.83% from 2024 to 2032, from USD 6.00 billion in 2024 to USD 8.42 billion.

The two main factors propelling market expansion are the rise in migraine issues worldwide and the growing public knowledge of new medication classes.

Growing public awareness of new drug classes and a rise in migraine problems globally are two factors influencing the target market's growth. It is also anticipated that the introduction of calcitonin gene-related peptide (CGRP) will facilitate the growth of this enterprise. Migraine is a recurrent, severe headache that is accompanied by photophobia, phonophobia, and nausea. Genes play a role in the development of illness. Out-of-balance emotions, including dejection, tension, anxiety, shock, and excitement, can cause migraine headaches. Each migraine attack varies in length and intensity and often affects one side of the head. Factors include an increase in migraine frequency with substantial unmet needs, rising R&D expenditures resulting in a sizable drug pipeline, and an increase in our understanding of migraine and available treatments.

Perspectives on Market Segments

The migraine market is divided into two divisions based on type: episodic and chronic.

The migraine market is divided into two segments based on the kind of treatment: preventive and abortive.

Surgery has divided the market data into three categories: triptans, ergots, and others.

Regional Perspectives on Migraines

The analysis offers market insights by region, including Asia-Pacific, Europe, North America, and the rest of the world. Throughout the study period, a notable compound annual growth rate (CAGR) is anticipated in the Asia Pacific migraine market. As healthcare expenses rise and infrastructure in emerging countries like China and India improves, the Asia Pacific acute migraine treatment market is predicted to grow in size. The easy availability of reasonably priced migraine treatment choices backed by growing regulatory body initiatives is another significant aspect that is probably propelling the regional market. by the Brand Equity Foundation of India.

The second largest market share is held by the migraine industry in Europe. Two reasons driving the target market's growth are the rise in migraine issues worldwide and the growing public knowledge of new medicine classes. Furthermore, the launch of calcitonin gene-related peptide (CGRP) is expected to support the growth of this sector.

From 2024 to 2032, the North American migraine market is anticipated to expand at the quickest compound annual growth rate. increasing financial contributions from powerful U.S.-based parties. The local market is expected to gain from the substantial research and development activities conducted in the US, Canada, and other nations to identify novel treatment choices. According to the American Family Physician, there are approximately 441.5 million adults in the United States, of whom 6-9% are men and 18-26% are women. In 2009, the United States suffered a migraine.

Key Players

Among the leading companies in the migraine market are Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Abbott Laboratories, Teva Pharmaceutical Industries Limited, Allergan Plc, Pfizer Inc., AstraZeneca, and Impax Laboratories.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 DRIVERS
  • 4.1.1 INCREASING INCIDENCES/PREVALENCE OF MIGRAINE
  • 4.1.2 RISING APPROVAL FOR THERAPEUTIC MIGRAINE PRODUCTS
• 4.2 RESTRAINTS
  • 4.2.1 VOLUNTARY PRODUCT RECALL BY MARKET PLAYERS
• 4.3 OPPORTUNITY
  • 4.3.1 ONGOING CLINICAL TRIALS ASSOCIATED WITH MIGRAINE EFFICACY AND SAFETY
• 4.4 PORTER'S FIVE FORCES MODEL
  • 4.4.1 THREAT OF NEW ENTRANTS
  • 4.4.2 BARGAINING POWER OF SUPPLIERS
  • 4.4.3 THREAT OF SUBSTITUTES
  • 4.4.4 BARGAINING POWER OF BUYERS
  • 4.4.5 INTENSITY OF RIVALRY
• 4.5 IMPACT OF COVID-19 ON GLOBAL MIGRAINE MARKET

5 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE

• 5.1 OVERVIEW
• 5.2 MIGRAINE WITH AURA
• 5.3 MIGRAINE WITHOUT AURA
• 5.4 OTHERS

6 GLOBAL MIGRAINE MARKET, BY TREATMENT

• 6.1 OVERVIEW
• 6.2 MEDICATION
  • 6.2.1 CGRP INHIBITORS
    • 6.2.1.1 RIMEGEPANT
    • 6.2.1.2 UBROGEPANT
    • 6.2.1.3 OTHERS
  • 6.2.2 TRIPTANS
    • 6.2.2.1 SUMATRIPTAN SUCCINATE
    • 6.2.2.2 ZOLMITRIPTAN
    • 6.2.2.3 RIZATRIPTAN
    • 6.2.2.4 OTHERS
  • 6.2.3 ERGOTS
    • 6.2.3.1 DIHYDROERGOTAMINE
    • 6.2.3.2 ERGOTAMINE TARTRATE
    • 6.2.3.3 OTHERS
  • 6.2.4 ACETYLCHOLINE INHIBITORS/ NEUROTOXINS
  • 6.2.5 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
  • 6.2.6 BETA-BLOCKERS
  • 6.2.7 CALCIUM CHANNEL BLOCKERS
  • 6.2.8 DITANS
  • 6.2.9 OTHERS
• 6.3 DEVICE-BASED THERAPIES
  • 6.3.1 ELECTRICAL NEUROMODULATION DEVICE
  • 6.3.2 TRANSCRANIAL MAGNETIC STIMULATION DEVICE
  • 6.3.3 VAGUS NERVE STIMULATION DEVICE
  • 6.3.4 OTHERS

7 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL

• 7.1 OVERVIEW
• 7.2 ONLINE
• 7.3 OFFLINE

8 GLOBAL MIGRAINE MARKET, BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 FRANCE
  • 8.3.3 UK
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 INDIA
  • 8.4.3 JAPAN
  • 8.4.4 SOUTH KOREA
  • 8.4.5 AUSTRALIA
  • 8.4.6 NEW ZEALAND
  • 8.4.7 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 MIDDLE EAST
  • 8.5.2 LATIN AMERICA
  • 8.5.3 AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 MARKET SHARE ANALYSIS, 2023
• 9.3 COMPETITOR DASHBOARD
• 9.4 PUBLIC PLAYERS STOCK SUMMARY
• 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 PRODUCT LAUNCH
  • 9.6.2 AGREEMENT
  • 9.6.3 PRODUCT APPROVAL
  • 9.6.4 COLLABORATION
  • 9.6.5 PRODUCT EXPANSION

10 COMPANY PROFILES

• 10.1 AMGEN INC
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 ELI LILLY AND COMPANY
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 ABBVIE INC.
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 BAUSCH HEALTH COMPANIES INC.
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 KEY STRATEGIES
• 10.5 GSK PLC
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCT OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 KEY STRATEGIES
• 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 KEY STRATEGIES
• 10.7 PFIZER INC.
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 KEY STRATEGIES
• 10.8 THERANICA BIO-ELECTRONICS LTD
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 CEFALY
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 ASTRAZENECA
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 SWOT ANALYSIS
  • 10.10.6 KEY STRATEGIES
• 10.11 DATA CITATIONS